Pivotal bioVenture Partners led a $100m Series C round in HotSpot Therapeutics.

Pivotal bioVenture Partners led a $100m Series C round in HotSpot Therapeutics, a biotechnology company, with participation from LSP, B Capital Group, Monashee Investment Management, CaaS Capital Management, Revelation Partners, Pavilion Capital, Atlas Venture, Sofinnova Partners, SR One Capital Management, Tekla Capital Management and MRL Ventures Fund. "With the support of top-tier healthcare and technology investors, we will expand on the significant productivity of the Smart Allostery™ platform to enable a treasure trove of sought-after disease targets and thereby develop medicines that broadly benefit patients," Jonathan Montagu, HotSpot Therapeutics CEO.